A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

AstraZeneca says early trial data indicates third dose helps against Omicron

By Pushkala Aripaka and Ludwig Burger Jan 13 (Reuters) - AstraZeneca AZN.L said on Thursday that preliminary data from a trial showed that its COVID-19 shot, Vaxzevria, generated an increase in antibodies against the Omicron and other variants when given as a third booster dose. The increased response, also against the Delta variant, was seen in a
A
P

UK Stocks-Factors to watch on Jan 13

Jan 13 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower, with futures FFIc1 down 0.1% on Thursday. * M&S: British retailer Marks & Spencer MKS.L nudged up its profit outlook after it reported a strong Christmas performance, particularly in food, where it outperformed the market. * ASTRAZENECA: AstraZeneca AZN.L said new data from tr
A
M
M
P
T
W
U

AstraZeneca says higher antibody response against Omicron with booster dose

Jan 13 (Reuters) - AstraZeneca AZN.L said on Thursday new data from trials showed there was a higher antibody response against the Omicron coronavirus variant and others, including Beta, Delta, Alpha and Gamma, when its vaccine was given as a third booster dose. Reporting by Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu
A

UK Stocks-Factors to watch on Jan 13

Jan 13 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower, with futures FFIc1 down 0.1% on Thursday. * ASTRAZENECA: AstraZeneca AZN.L said on Wednesday the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19. * FINANCE: Britain's financial services grew for th
A
M
M
P
T
W
U

Yields higher after progress on Omicron, rising stocks

By Ross Kerber Dec 23 (Reuters) - Traders steepened the U.S. Treasury yield curve on Thursday as stock markets rose on optimism about the public health impact of the Omicron coronavirus variant. The benchmark 10-year yield US10YT=RR was up 3.5 basis points at 1.4926% in afternoon trading, with Treasury markets set to close early at 2 p.m. ET (1900
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.